JPMorgan Diversified Return International Eqty ETF vs 22nd Century Group Inc — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73.01 (market cap $378.77M), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: JPMorgan Diversified Return International Eqty ETF is far larger — about 609.3× 22nd Century Group Inc's market cap, and JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Diversified Return International Eqty ETF for 120 Days and 22nd Century Group Inc for 32 Days on average.
| JPIN | XXII | |
|---|---|---|
Market Cap | $378.77M | $621.67K |
Volume | 13,861 | 45,625 |
52-Week High | $77.80 | $483.00 |
52-Week Low | $64.96 | $0.80 |
Typical Hold Time | 120 Days | 32 Days |
Sector | — | Consumer Staples |
Enterprise Value | — | -$3.69M |
Signals from Pluang's Aura AI — not financial advice
JPIN trades at $73.01, up 0.1% on the day, but technical indicators signal a bearish trend with 21 sell signals versus 2 buy signals. The ETF exhibits oversold conditions with RSI readings below 25, while moving averages and ADX reinforce downward momentum. A dividend of $0.51 is scheduled for payment in September 2026, offering income potential amid weak price action.
The outlook remains cautious due to strong bearish technical pressure, though oversold RSI levels may attract contrarian buyers. Risks include persistent selling pressure and reliance on international equity markets. Investment appeal hinges on dividend yield and potential mean reversion if broader market sentiment improves.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →